EDIT · Editas Medicine Inc. Common Stock
View on chartInsiders & Stakes
| Gilmore Neil O'Neill CEO | ▼ Sell | Open Market | 243,189 Shares held | 9/3/2026 | View profile |
| Mei Baisong SVP, CHIEF MEDICAL OFFICER | ▼ Sell | Open Market | 133,354 Shares held | 12/3/2024 | View profile |
| Erick Lucera Chief Financial Officer | ▼ Sell | Open Market | 112,720 Shares held | 3/4/2025 | View profile |
| Michelle Robertson Director | ▼ Sell | Open Market | 106,610 Shares held | 5/11/2023 | View profile |
| MULLEN JAMES C Director | ▼ Sell | Open Market | 75,898 Shares held | 1/3/2022 | View profile |
| Eaton Bruce EVP, Chief Business Officer | ▼ Sell | Open Market | 74,791 Shares held | 12/5/2023 | View profile |
| Jessica Hopfield Director | ▲ Buy | Open Market | 67,700 Shares held | 5/13/2024 | View profile |
| Shearman Mark S EVP, Chief Scientific Officer | ▼ Sell | Open Market | 65,559 Shares held | 2/13/2023 | View profile |
| Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | ▼ Sell | Open Market | 61,660 Shares held | 9/3/2026 | View profile |
| Michaels Lisa Anne EVP/Chief Medical Officer | ▲ Buy | Grant | 22,675 Shares held | 12/22/2021 | View profile |
| Amy Parison SVP, Chief Financial Officer | ▼ Sell | Open Market | 13,839 Shares held | 9/3/2026 | View profile |
Transaction History
| Linda Burkly | ▼ Sell | Open Market | 709 | $2K | 9/3/2026 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 5,124 | $16K | 9/3/2026 |
| Amy Parison | ▼ Sell | Open Market | 453 | $1K | 9/3/2026 |
| Amy Parison | ▼ Sell | Open Market | 678 | $2K | 8/3/2026 |
| Linda Burkly | ▼ Sell | Open Market | 4,928 | $13K | 7/28/2026 |
| Amy Parison | ▼ Sell | Open Market | 464 | $1K | 6/3/2026 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 15,380 | $42K | 6/3/2026 |
| Linda Burkly | ▼ Sell | Open Market | 731 | $2K | 6/3/2026 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 5,394 | $11K | 3/3/2026 |
| Amy Parison | ▼ Sell | Open Market | 474 | $957 | 3/3/2026 |
| Linda Burkly | ▼ Sell | Open Market | 749 | $2K | 3/3/2026 |
| Amy Parison | ▼ Sell | Open Market | 461 | $993 | 12/3/2025 |
| Linda Burkly | ▼ Sell | Open Market | 713 | $2K | 12/3/2025 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 5,603 | $12K | 12/3/2025 |
| Linda Burkly | ▼ Sell | Open Market | 710 | $2K | 9/3/2025 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 5,592 | $15K | 9/3/2025 |
| Amy Parison | ▼ Sell | Open Market | 458 | $1K | 9/3/2025 |
| Amy Parison | ▼ Sell | Open Market | 679 | $2K | 8/7/2025 |
| Linda Burkly | ▼ Sell | Open Market | 5,121 | $13K | 7/31/2025 |
| Linda Burkly | ▼ Sell | Open Market | 726 | $1K | 6/3/2025 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 15,192 | $26K | 6/3/2025 |
| Amy Parison | ▼ Sell | Open Market | 446 | $769 | 6/3/2025 |
| Erick Lucera | ▼ Sell | Open Market | 4,109 | $7K | 3/4/2025 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 16,632 | $28K | 3/4/2025 |
| Linda Burkly | ▼ Sell | Open Market | 2,891 | $5K | 3/4/2025 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 1,618 | $3K | 12/3/2024 |
| Mei Baisong | ▼ Sell | Open Market | 541 | $1K | 12/3/2024 |
| Mei Baisong | ▼ Sell | Open Market | 518 | $2K | 9/4/2024 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 1,555 | $5K | 9/4/2024 |
| Linda Burkly | ▼ Sell | Open Market | 11,886 | $64K | 7/25/2024 |
| Mei Baisong | ▼ Sell | Open Market | 6,619 | $34K | 7/19/2024 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 12,191 | $67K | 6/4/2024 |
| Mei Baisong | ▼ Sell | Open Market | 511 | $3K | 6/4/2024 |
| Erick Lucera | ▼ Sell | Open Market | 22,337 | $125K | 5/20/2024 |
| Jessica Hopfield | ▲ Buy | Open Market | 45,000 | $254K | 5/13/2024 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 77,824 | $733K | 3/5/2024 |
| Mei Baisong | ▼ Sell | Open Market | 20,327 | $191K | 3/4/2024 |
| Erick Lucera | ▲ Buy | Grant | 25,966 | $0 | 3/2/2024 |
| Linda Burkly | ▲ Buy | Grant | 15,055 | $0 | 3/2/2024 |
| Gilmore Neil O'Neill | ▲ Buy | Grant | 72,213 | $0 | 3/2/2024 |
| Mei Baisong | ▲ Buy | Grant | 50,900 | $0 | 3/2/2024 |
| Mei Baisong | ▲ Buy | Grant | 19,458 | $0 | 3/2/2024 |
| Mei Baisong | ▲ Buy | Grant | 19,457 | $0 | 3/2/2024 |
| Linda Burkly | ▲ Buy | Grant | 24,800 | $0 | 3/2/2024 |
| Erick Lucera | ▲ Buy | Grant | 35,300 | $0 | 3/2/2024 |
| Gilmore Neil O'Neill | ▲ Buy | Grant | 130,700 | $0 | 3/2/2024 |
| Gilmore Neil O'Neill | ▲ Buy | Grant | 72,212 | $0 | 3/2/2024 |
| Eaton Bruce | ▼ Sell | Open Market | 103 | $1K | 12/5/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 695 | $6K | 11/14/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 139 | $1K | 11/7/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 103 | $908 | 9/6/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 702 | $6K | 8/11/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 141 | $1K | 8/8/2023 |
| Linda Burkly | ▲ Buy | Grant | 45,167 | $0 | 7/24/2023 |
| Mei Baisong | ▼ Sell | Open Market | 4,317 | $38K | 7/19/2023 |
| Gilmore Neil O'Neill | ▼ Sell | Open Market | 6,486 | $62K | 6/5/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 105 | $998 | 6/5/2023 |
| Erick Lucera | ▲ Buy | Grant | 77,900 | $0 | 5/17/2023 |
| Michelle Robertson | ▼ Sell | Open Market | 949 | $9K | 5/11/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 668 | $7K | 5/11/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 135 | $1K | 5/9/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 101 | $898 | 3/3/2023 |
| Michelle Robertson | ▼ Sell | Open Market | 184 | $2K | 3/3/2023 |
| Gilmore Neil O'Neill | ▲ Buy | Grant | 50,000 | $0 | 3/2/2023 |
| Eaton Bruce | ▲ Buy | Grant | 16,700 | $0 | 3/2/2023 |
| Mei Baisong | ▲ Buy | Grant | 18,000 | $0 | 3/2/2023 |
| Michelle Robertson | ▲ Buy | Grant | 31,500 | $0 | 3/2/2023 |
| Shearman Mark S | ▼ Sell | Open Market | 2,790 | $27K | 2/13/2023 |
| Michelle Robertson | ▼ Sell | Open Market | 4,287 | $41K | 2/13/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 3,307 | $32K | 2/13/2023 |
| Eaton Bruce | ▼ Sell | Open Market | 346 | $4K | 2/7/2023 |
| Michelle Robertson | ▼ Sell | Open Market | 1,752 | $14K | 1/10/2023 |
| Michelle Robertson | ▼ Sell | Open Market | 193 | $2K | 12/5/2022 |
| Eaton Bruce | ▼ Sell | Open Market | 102 | $1K | 12/5/2022 |
| Eaton Bruce | ▼ Sell | Open Market | 289 | $3K | 11/8/2022 |
| Michelle Robertson | ▼ Sell | Open Market | 192 | $3K | 9/6/2022 |
| Eaton Bruce | ▼ Sell | Open Market | 101 | $2K | 9/6/2022 |
| Eaton Bruce | ▼ Sell | Open Market | 293 | $5K | 8/9/2022 |
| Mei Baisong | ▲ Buy | Grant | 58,372 | $0 | 7/18/2022 |
| Shearman Mark S | ▼ Sell | Open Market | 5,145 | $52K | 6/15/2022 |
| Eaton Bruce | ▼ Sell | Open Market | 1,123 | $13K | 6/3/2022 |
| Michelle Robertson | ▼ Sell | Open Market | 1,527 | $18K | 6/3/2022 |
| Gilmore Neil O'Neill | ▲ Buy | Grant | 86,655 | $0 | 6/2/2022 |
| Eaton Bruce | ▼ Sell | Open Market | 297 | $4K | 5/9/2022 |
| Eaton Bruce | ▼ Sell | Open Market | 1,258 | $25K | 4/1/2022 |
| Eaton Bruce | ▼ Sell | Open Market | 403 | $7K | 3/3/2022 |
| Michelle Robertson | ▼ Sell | Open Market | 767 | $13K | 3/3/2022 |
| Eaton Bruce | ▲ Buy | Grant | 37,593 | $0 | 2/10/2022 |
| Shearman Mark S | ▲ Buy | Grant | 31,709 | $0 | 2/10/2022 |
| Michelle Robertson | ▲ Buy | Grant | 53,499 | $0 | 2/10/2022 |
| Eaton Bruce | ▼ Sell | Open Market | 302 | $5K | 2/8/2022 |
| Michelle Robertson | ▼ Sell | Open Market | 1,744 | $45K | 1/11/2022 |
| MULLEN JAMES C | ▼ Sell | Open Market | 18,252 | $492K | 1/3/2022 |
| Eaton Bruce | ▲ Buy | Grant | 3,472 | $0 | 12/22/2021 |
| Michaels Lisa Anne | ▲ Buy | Grant | 4,243 | $0 | 12/22/2021 |
| Shearman Mark S | ▲ Buy | Grant | 9,084 | $0 | 12/22/2021 |
| MULLEN JAMES C | ▲ Buy | Grant | 36,477 | $0 | 12/22/2021 |
| Michelle Robertson | ▲ Buy | Grant | 4,471 | $0 | 12/22/2021 |
| Michaels Lisa Anne | ▼ Sell | Open Market | 1,568 | $60K | 11/12/2021 |
| Eaton Bruce | ▼ Sell | Open Market | 287 | $12K | 11/9/2021 |
| MULLEN JAMES C | ▼ Sell | Open Market | 13,805 | $525K | 10/18/2021 |
| MULLEN JAMES C | ▲ Buy | Grant | 36,478 | $0 | 9/30/2021 |
| Eaton Bruce | ▼ Sell | Open Market | 287 | $16K | 8/9/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target
Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.